Current treatment options for HER2-positive breast cancer patients with brain metastases
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference93 articles.
1. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study;Andersson;J. Clin. Oncol.,2011
2. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial;Aoyama;JAMA,2006
3. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis;Auchter;Int. J. Radiat. Oncol. Biol. Phys.,1996
4. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study;Bachelot;Lancet Oncol.,2013
5. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer;Bartsch;J. Neurooncol.,2007
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?;Critical Reviews in Oncology/Hematology;2024-03
2. Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting;Breast Cancer: Targets and Therapy;2024-03
3. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer;Frontiers in Oncology;2024-01-16
4. Neratinib for HER2-positive breast cancer with an overlooked option;Molecular Medicine;2023-10-06
5. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report;Frontiers in Oncology;2023-08-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3